Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DH3S7V
|
|||
| Drug Name |
CVN424
|
|||
| Synonyms |
CVN424; XO01711URG; CVN-424; 2254706-21-1; UNII-XO01711URG; CHEMBL4778540; Ethanone, 1-(2-(4-(2,4-difluorophenoxy)-1-piperidinyl)-7,8-dihydro-3-(((3R)-tetrahydro-3-furanyl)amino)pyrido(3,4-b)pyrazin-6(5H)-yl)-; 1-[2-[4-(2,4-difluorophenoxy)piperidin-1-yl]-3-[[(3R)-oxolan-3-yl]amino]-7,8-dihydro-5H-pyrido[3,4-b]pyrazin-6-yl]ethanone; SCHEMBL20584477; GTPL11514; BDBM50582450; AKOS040759781; AT37427; HY-134661A; compound 6i [PMID: 33861086]; MS-28775; CS-0163733; Z3664677849
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 2 | [1] | |
| Company |
Cerevance Beta, Inc.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H29F2N5O3
|
|||
| Canonical SMILES |
CC(=O)N1CCC2=C(C1)N=C(C(=N2)N3CCC(CC3)OC4=C(C=C(C=C4)F)F)NC5CCOC5
|
|||
| InChI |
InChI=1S/C24H29F2N5O3/c1-15(32)31-10-6-20-21(13-31)28-23(27-17-7-11-33-14-17)24(29-20)30-8-4-18(5-9-30)34-22-3-2-16(25)12-19(22)26/h2-3,12,17-18H,4-11,13-14H2,1H3,(H,27,28)/t17-/m1/s1
|
|||
| InChIKey |
HSWVJQBEXRKOBZ-QGZVFWFLSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | G-protein coupled receptor 6 (GPR6) | Target Info | Agonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04191577) A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations. U.S.National Institutes of Health. | |||
| REF 2 | Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease. J Pharmacol Exp Ther. 2021 Jun;377(3):407-416. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.